BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 24268590)

  • 1. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus.
    Leung YH; Lim WL; Wong MH; Chuang SK
    Epidemiol Infect; 2012 May; 140(5):814-7. PubMed ID: 21801465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
    Cao B; Li XW; Mao Y; Wang J; Lu HZ; Chen YS; Liang ZA; Liang L; Zhang SJ; Zhang B; Gu L; Lu LH; Wang DY; Wang C;
    N Engl J Med; 2009 Dec; 361(26):2507-17. PubMed ID: 20007555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.
    Ling LM; Chow AL; Lye DC; Tan AS; Krishnan P; Cui L; Win NN; Chan M; Lim PL; Lee CC; Leo YS
    Clin Infect Dis; 2010 Apr; 50(7):963-9. PubMed ID: 20180701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.
    Paton NI; Lee L; Xu Y; Ooi EE; Cheung YB; Archuleta S; Wong G; Wilder-Smith A
    Lancet Infect Dis; 2011 Sep; 11(9):677-83. PubMed ID: 21550310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.
    Duan ZP; Jia ZH; Zhang J; Liu S; Chen Y; Liang LC; Zhang CQ; Zhang Z; Sun Y; Zhang SQ; Wang YY; Wu YL
    Chin Med J (Engl); 2011 Sep; 124(18):2925-33. PubMed ID: 22040504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a new bioequivalent formulation of oseltamivir (Enfluvir®) on 2010-2011 seasonal influenza viruses: an open phase IV study.
    Ceyhan M; Karadag Oncel E; Badur S; Ciblak MA; Alhan E; Celik US; Kurugol Z; Saz EU; Ozsurekci Y; Celik M; Parlakay AO
    Int J Infect Dis; 2012 Apr; 16(4):e273-8. PubMed ID: 22310296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
    Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
    J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
    Rath B; von Kleist M; Tief F; Karsch K; Tuerk E; Muehlhans S; Louis F; Skopnik H; Schweiger B; Duwe S
    Pediatr Infect Dis J; 2012 Sep; 31(9):899-905. PubMed ID: 22581220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pandemic Influenza A (H1N1) 2009 in India: duration of virus shedding in patients under antiviral treatment.
    Gandhoke I; Rawat DS; Rai A; Khare S; Ichhpujani RL
    Indian J Med Microbiol; 2011; 29(1):37-41. PubMed ID: 21304193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Dawood FS; Jara J; Gonzalez R; Castillo JM; De León T; Estripeaut D; Luciani K; Sujey Brizuela Y; Barahona A; Cazares RA; Lawson AM; Rodriguez M; de Viana D; Franco D; Castillo M; Fry AM; Gubareva L; Tamura D; Hughes M; Gargiullo P; Clara W; Azziz-Baumgartner E; Widdowson MA
    Antiviral Res; 2016 Sep; 133():85-94. PubMed ID: 27451343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.